ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) CEO Richard E. Lowenthal sold 100,000 shares of the stock in a transaction dated Tuesday, April 9th. The stock was sold at an average price of $9.28, for a total transaction of $928,000.00. Following the completion of the sale, the chief executive officer now directly owns 1,646,494 shares in the company, valued at $15,279,464.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
ARS Pharmaceuticals Price Performance
Shares of SPRY opened at $9.27 on Thursday. The firm's 50 day simple moving average is $8.42 and its 200 day simple moving average is $6.04. The company has a market capitalization of $894.56 million, a P/E ratio of -16.26 and a beta of 0.83. ARS Pharmaceuticals, Inc. has a 1-year low of $2.55 and a 1-year high of $11.27.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on SPRY shares. Leerink Partnrs raised shares of ARS Pharmaceuticals from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 5th. SVB Leerink raised shares of ARS Pharmaceuticals from a "market perform" rating to an "outperform" rating and increased their price target for the stock from $6.00 to $18.00 in a report on Tuesday, March 5th. Wedbush reissued an "outperform" rating and issued a $19.00 price target on shares of ARS Pharmaceuticals in a report on Monday, March 11th. Finally, William Blair raised shares of ARS Pharmaceuticals from a "market perform" rating to an "outperform" rating in a report on Tuesday, February 20th.
Your bank is lying to you.
From MyBankTracker | Ad
You might think you have your money in a high-yield savings account, but do you really? The national average APY on savings is just 0.58%, but you can get up to 5.0% APY online with these accounts.
View the best savings account rates here
View Our Latest Report on ARS Pharmaceuticals
Institutional Investors Weigh In On ARS Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. GSA Capital Partners LLP purchased a new stake in ARS Pharmaceuticals in the fourth quarter valued at approximately $632,000. Barclays PLC raised its stake in shares of ARS Pharmaceuticals by 127.1% during the fourth quarter. Barclays PLC now owns 40,374 shares of the company's stock worth $222,000 after acquiring an additional 22,597 shares in the last quarter. Nantahala Capital Management LLC raised its stake in shares of ARS Pharmaceuticals by 45.3% during the fourth quarter. Nantahala Capital Management LLC now owns 1,596,504 shares of the company's stock worth $8,749,000 after acquiring an additional 497,429 shares in the last quarter. Creative Planning raised its stake in shares of ARS Pharmaceuticals by 11.7% during the fourth quarter. Creative Planning now owns 31,201 shares of the company's stock worth $171,000 after acquiring an additional 3,270 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of ARS Pharmaceuticals during the fourth quarter worth approximately $423,000. 68.16% of the stock is owned by hedge funds and other institutional investors.
ARS Pharmaceuticals Company Profile
(
Get Free Report)
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
